AN2 Therapeutics
Stock Forecast, Prediction & Price Target
AN2 Therapeutics Financial Estimates
AN2 Therapeutics Revenue Estimates
AN2 Therapeutics EBITDA Estimates
AN2 Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $33.2M Low: $33.2M High: $33.2M avg. 0% | Avg: $27.77M Low: $27.77M High: $27.77M avg. -16.34% | Avg: $248.7M Low: $248.7M High: $248.7M avg. 795.40% | Avg: $566.35M Low: $566.35M High: $566.35M avg. 127.72% |
Net Income
% change YoY
| $-21.47M N/A | $-41.47M -93.11% | $-64.73M -56.09% | Avg: $-91.53M Low: $-64.19M High: $-40.35M avg. -41.40% | Avg: $-45.5M Low: $-31.86M High: $-6.37M avg. 50.29% | Avg: $95.34M Low: $95.34M High: $95.34M avg. 309.54% | Avg: $269.39M Low: $269.39M High: $269.39M avg. 182.54% |
EBITDA
% change YoY
| $-21.57M N/A | $-42.26M -95.89% | $4.90M 111.60% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.15 N/A | -$2.14 -86.08% | -$2.74 -28.03% | Avg: -$2.38 Low: -$2.72 High: -$1.71 avg. 13.22% | Avg: -$0.71 Low: -$1.35 High: -$0.27 avg. 70.27% | Avg: $4.04 Low: $4.04 High: $4.04 avg. 671.69% | Avg: $11.42 Low: $11.42 High: $11.42 avg. 182.54% |
Operating Expenses
% change YoY
| $21.57M N/A | $42.26M 95.89% | $69.63M 64.76% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is AN2 Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 125.24% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -64.19M, average is -91.53M and high is -40.35M.
What is AN2 Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 226.69% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $33.2M, average is $33.2M and high is $33.2M.
What is AN2 Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 234.43% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$2.72, average is -$2.38 and high is $-1.71.
What is the best performing analyst?
In the last twelve months analysts have been covering AN2 Therapeutics stock. The most successful analyst is Joseph Schwartz.